Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study

Background Mild cognitive impairment (MCI) of an amnestic type is a common condition in older people and highly predictive of Alzheimer's disease (AD). To date, there is no clear consensus regarding the best antecedent biomarker to predict early conversion to AD. Objective The aim of the study is to demonstrate that 1H magnetic resonance spectroscopy (MRS) of the brain in MCI patients may predict early conversion to dementia within the 2-year period after baseline assessment. Methods A cohort of patients fulfilling the criteria of amnestic MCI were enrolled consecutively. At baseline the patients underwent neuropsychological examination, standard blood tests and APOE genotype. 1H-MRS (1.5 T) of the brain was carried out by exploring two areas: the posteromedial bilateral parietal lobe and left medial occipital lobe. The patients were followed up to detect conversion to probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association group criteria. Results After a 2-year follow-up, 27 (38%) patients converted to AD. The mean N-acetyl-aspartate/creatine (NAA/Cr) ratio in the posteromedial bilateral parietal cortex was 1.38 in converters versus 1.49 in non-converters (p<0.0001). An NAA/Cr ratio equal to or lower than 1.43 in this area predicted conversion to probable AD at 74.1% sensitivity and 83.7% specificity (area under the curve: 0.84; 95% CI 0.73 to 0.92). The cross-validated accuracy of classification was 82%, which reaches 85% when the APOE4 genotype and memory test are included in the analysis. In the left medial occipital lobe, the predictive value was somewhat lower with 85.2% sensitivity and 61.4% specificity (area under the curve: 0.8; 95% CI 0.69 to 0.89). Neither the APOE4 genotype nor leuco-araiosis was predictive of conversion to dementia. Conclusion MRS is a valuable biomarker to predict early conversion to dementia in patients with amnestic MCI.

[1]  B D Ross,et al.  Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. , 1993, Radiology.

[2]  Patrizia Mecocci,et al.  Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy , 2006, Neurobiology of Aging.

[3]  S. Olmos,et al.  Physical Basis of Magnetic Resonance Spectroscopy and its Application to Central Nervous System Diseases , 2006 .

[4]  Nicola Vanacore,et al.  Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials , 2007, PLoS medicine.

[5]  C. Jack,et al.  MRS in presymptomatic MAPT mutation carriers , 2010, Neurology.

[6]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[7]  Sudha Seshadri,et al.  Visual Association Pathology in Preclinical Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.

[8]  S. Leurgans,et al.  MRI predictors of risk of incident Alzheimer disease , 2005, Neurology.

[9]  Kuncheng Li,et al.  Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and alzheimer disease , 2009, Acta radiologica.

[10]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[11]  A. Ivanoiu,et al.  Cerebrospinal fluid TAU protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer’s disease and correlation with the neuropsychological examination , 2005, Neurocase.

[12]  P. Bartenstein,et al.  Association between Cognitive Performance and Cortical Glucose Metabolism in Patients with Mild Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[13]  M N Rossor,et al.  MRS shows abnormalities before symptoms in familial Alzheimer disease , 2006, Neurology.

[14]  Heinrich Lanfermann,et al.  Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy , 2009, Psychiatry Research: Neuroimaging.

[15]  Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: Early right hippocampal NAA/Cr loss in mildly impaired subjects , 2008, Psychiatry Research: Neuroimaging.

[16]  Anders Wallin,et al.  Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. , 2005, Clinical chemistry.

[17]  Kaj Blennow,et al.  Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. , 2003, Acta neurologica Scandinavica. Supplementum.

[18]  E G Tangalos,et al.  Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease , 2000, Neurology.

[19]  E. Zimmerman,et al.  1H MR spectroscopy using TE averaged PRESS: A more sensitive technique to detect neurodegeneration associated with Alzheimer's disease , 2005, Magnetic resonance in medicine.

[20]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[21]  H. Amièva,et al.  Incidence and outcome of mild cognitive impairment in a population-based prospective cohort , 2002, Neurology.

[22]  M. Oremus,et al.  Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. , 2002, Clinical therapeutics.

[23]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[24]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[25]  Henrik Zetterberg,et al.  Cerebrospinal fluid markers for prediction of Alzheimer's disease , 2003, Neuroscience Letters.

[26]  P. Modrego,et al.  Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. , 2006, Current Alzheimer research.

[27]  Brian D. Ross,et al.  Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases , 1999 .

[28]  Philip Scheltens,et al.  Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment , 2004, Neurology.

[29]  Uwe Haberkorn,et al.  Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease , 2007, Psychiatry Research: Neuroimaging.

[30]  Gwenn S. Smith,et al.  The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. , 1993, AJNR. American journal of neuroradiology.

[31]  D. Perani,et al.  Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. , 2005, Archives of neurology.

[32]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[33]  L. Flicker,et al.  Donepezil for mild cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[34]  A Drzezga,et al.  Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. , 2002, Archives of neurology.

[35]  W F Stewart,et al.  Screening for dementia with the Memory Impairment Screen , 1999, Neurology.

[36]  P. Scheltens,et al.  Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment , 2002, Journal of neurology, neurosurgery, and psychiatry.

[37]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[38]  Brian Ross.  Basic Physics of MRS , 1999 .

[39]  N. Fayed,et al.  Comparative test–retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software , 2009, Neurological research.

[40]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[41]  A. Drzezga,et al.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[43]  B D Ross,et al.  Probable Alzheimer disease: diagnosis with proton MR spectroscopy. , 1995, Radiology.

[44]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[45]  M. Bobinski,et al.  Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Jack,et al.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. , 2008, Radiology.

[47]  N. Fayed,et al.  Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy , 2010, European journal of neurology.

[48]  R. Killiany,et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.

[49]  J. Pettegrew,et al.  N‐acetyl‐L‐aspartate and other amino acid metabolites in Alzheimer's disease brain , 1992, Neurology.

[50]  D. Bennett,et al.  MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease☆ ☆ This research was supported by grants P01 AG09466 and P30 AG10161 from the National Institute on Aging, National Institutes of Health. , 2001, Neurobiology of Aging.

[51]  A. Waldman,et al.  Brain proton spectroscopy in dementia: an aid to clinical diagnosis , 1999, The Lancet.

[52]  A. Convit,et al.  Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment , 2002, Neuroscience Letters.

[53]  N. Fayed,et al.  Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. , 2008, Academic radiology.

[54]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[55]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[56]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[57]  A. Lobo,et al.  [Cognocitive mini-test (a simple practical test to detect intellectual changes in medical patients)]. , 1979, Actas luso-espanolas de neurologia, psiquiatria y ciencias afines.

[58]  E G Tangalos,et al.  1H MR spectroscopy in common dementias , 2004, Neurology.

[59]  E. Tangalos,et al.  Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.

[60]  S. Leurgans,et al.  MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD , 2004, Neurobiology of Aging.

[61]  Kaj Blennow,et al.  Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .

[62]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[63]  Anders Wallin,et al.  Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment , 2005 .

[64]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.